The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancer
Not Applicable
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000015404
- Lead Sponsor
- Department of Clinical Oncology, Akita University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. with potent drug affected activity of CYP3A4 or UGT1A9, and with potent drug affected blood concentration of regorafenib. 2. Pregnant female, possibly pregnant females and females feeding babies. 3. with uncontrollable hypertension (systolic >150 mmHg or diastolic >90 mmHg even with hypotensives) 4. with a history of embolism, ischemic heart disease, unstable angina, heart failure or cerebrovascular disease. 5. with severe allergy. 6. Any other patients whom the physician in charge of the study judges to be unsuitable.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method